ELIGARD
Atrix Laboratories has received FDA approval for a 3-month sustained-release treatment for advanced prostate cancer. Indicated for palliative treatment, Eligard 22.5 mg (leuprolide acetate for injectable suspension) suppresses tumor growth in patients with hormoneresponsive prostate cancer. Injected S.C., the drug forms a solid implant under the skin. The drug is slowly released over 3 months as the implant is absorbed. This follows the January approval of Eligard 7.5 mg, which releases leuprolide over 1 month. Sustained levels of leuprolide decrease testosterone, which encourages growth of hormone-responsive tumors.
Eligard 22.5 mg will be copromoted with Atrix by Sanofi-Synthelabo.
Copyright Springhouse Corporation Nov 2002
Provided by ProQuest Information and Learning Company. All rights Reserved